Slide Shows


New Drugs Approved In December

10 Gene Therapy Companies Unignorable in 2019 The concept of gene therapy, which originated in the late 1960s, has come a long way – having had its own share of significant setbacks and gargantuan success.

10 RNA Therapeutics Companies To Watch In 2019 After decades of research and development in RNA interference (RNAi), considered one of the most exciting discoveries in biology, the year 2018 saw the first ever RNAi drug pass regulatory muster in the United States.

Biotech Stocks Facing FDA Decision In January 2019 As 2018 fades, it’s time to take a look at the drug candidates lined up at the FDA altar awaiting the federal agency’s decision in January 2019.

Supreme Cannabis Supreme Cannabis Company Inc. (FIRE.V) engages in the production of medical cannabis in Canada. The Toronto-based company was formerly known as Supreme Pharmaceuticals and changed its name to Supreme Cannabis Company, Inc. in December 2017. 7ACRES, the company’s wholly-owned subsidiary and flagship brand, is a federally licensed producer of cannabis operating inside a 342,000-square-foot facility in Kincardine, Ontario. It is en route to becoming Canada’s leading cultivator of consistently great commercial cannabis. In November, the company reported revenues for the first quarter of C$5.14 million, a 229 percent increase from the year-ago period’s C$1.56 million, and a 45 percent increase from the previous quarter.

New Drugs Approved In November The process of drug development is challenging. Some drugs pass the FDA muster easily, while some face a host of hurdles before getting the official stamp of approval.

MPX Bioceutical MPX Bioceutical Corp. (MPX.CN) is a Toronto-based cannabis company focused on the medical and adult use cannabis markets. The company is expanding its presence in the U.S., with imminent plans for ten dispensaries and four production facilities in four states. In August 2018, MPX Bioceutical was advised that its application for Licensed Producer status from Health Canada was at the Detailed Review and Initiation of Security Clearance Process stage. The company has started construction of its 72,342 square foot production facility. With all production facilities, MPX Bioceutical anticipates that it will have 9 million grams per annum in cultivation capacity and be able to produce 1.2 million grams of concentrates.

Charlotte’s Web Holdings Boulder, Colorado-based Charlotte’s Web Holdings Inc. (CWEB.CN) distributes hemp-based cannabidiol or CBD wellness products. Its products include CBD hemp oils, capsules, topicals, and pet products that feature CBD hemp oil extracts. Charlotte's Web Holdings sells its products online as well as through distributors, and brick and mortar retailers. Formerly known as Stanley Brothers Holdings Inc., the company changed its name to Charlotte's Web Holdings in July 2018. Charlotte’s Web grows its proprietary Industrial Hemp on farms leased in eastern Colorado and also sources Industrial Hemp through contract farming operations in Kentucky and Oregon. In October, the company said it has surpassed 3,000 retail locations across the U.S.

Biotech Stocks Facing FDA Decision In December With already 51 new molecular entities, or NMEs, getting greenlighted by the FDA so far this year, and still 1 more month to go, 2018 could be a banner year. This outpaces the 53 new drugs approved in 1996 - the highest ever.

New Drugs Approved In October The process of drug development is challenging. Some drugs pass the FDA muster easily, while some face a host of hurdles before getting the official stamp of approval.